dr. pal on the rationale for the tivo-3 trial with tivozanib in advanced rcc
Published 3 years ago • 133 plays • Length 0:52Download video MP4
Download video MP3
Similar videos
-
1:24
dr. motzer on the tivo-1 trial with tivozanib in advanced rcc
-
1:28
dr. motzer on the tivo-3 trial examining tivozanib in advanced rcc
-
1:05
dr. pal on potential tivozanib-based combinations in rcc
-
12:49
the tivo-3 study of tivozanib in metastatic renal cell carcinoma
-
0:50
dr. pal on the benefit of tivozanib in later-line settings for refractory rcc
-
10:19
early t-cell precursor lymphoblastic leukemia (etp-all)
-
1:00:22
cellular response to injurious stimulus - part 1
-
2:50
dr. ben george, hematologist/oncologist
-
1:44
tivo-3: tivozanib hydrochloride vs sorafenib for refractory advanced rcc
-
1:00
dr. vaishampayan on the potential of tivozanib in advanced rcc
-
2:04
sumanta k. pal, md, shares thoughts on the tivo-3 trial from asco gu 2021
-
1:41
tivozanib tolerability shows potential advantage for patients with advanced rcc
-
2:06
dr. rini discusses tivozanib in advanced rcc
-
1:15
dr. vaishampayan on the safety of tivozanib versus sorafenib in rcc
-
1:33
dr. pal on the checkmate-214 and cabosun studies in rcc
-
2:07
dr. subbiah on the importance of tivozanib in rcc
-
0:48
dr. pal on preoperative immunotherapy in patients with rcc
-
0:48
dr. pal discusses the role of pd-l1 in metastatic rcc
-
5:56
the rationale for cabozantinib in advanced rcc
-
4:42
asco: tivozanib for metastatic renal cell carcinoma
-
4:18
tivozanib for refractory advanced rcc
-
2:42
latest from tivo-3: tivozanib for refractory advanced renal cell carcinoma